A detailed history of Gateway Investment Advisers LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Gateway Investment Advisers LLC holds 111,555 shares of BMY stock, worth $6.6 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
111,555
Previous 111,566 0.01%
Holding current value
$6.6 Million
Previous $5.77 Million 9.28%
% of portfolio
0.07%
Previous 0.06%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 14, 2025

SELL
$51.92 - $59.94 $571 - $659
-11 Reduced 0.01%
111,555 $6.31 Million
Q3 2024

Oct 10, 2024

BUY
$39.66 - $51.75 $9,518 - $12,420
240 Added 0.22%
111,566 $5.77 Million
Q2 2024

Jul 12, 2024

BUY
$40.25 - $52.99 $523 - $688
13 Added 0.01%
111,326 $4.62 Million
Q1 2024

Apr 12, 2024

SELL
$47.98 - $54.4 $22 Million - $24.9 Million
-458,478 Reduced 80.46%
111,313 $6.04 Million
Q4 2023

Jan 09, 2024

SELL
$48.48 - $57.85 $2.5 Million - $2.98 Million
-51,529 Reduced 8.29%
569,791 $29.2 Million
Q3 2023

Oct 19, 2023

SELL
$57.89 - $64.73 $1.2 Million - $1.34 Million
-20,733 Reduced 3.23%
621,320 $36.1 Million
Q2 2023

Jul 13, 2023

BUY
$63.71 - $70.74 $573,517 - $636,801
9,002 Added 1.42%
642,053 $41.1 Million
Q1 2023

Apr 11, 2023

SELL
$65.71 - $74.53 $169,006 - $191,691
-2,572 Reduced 0.4%
633,051 $43.9 Million
Q4 2022

Jan 13, 2023

SELL
$68.48 - $81.09 $5.79 Million - $6.85 Million
-84,510 Reduced 11.74%
635,623 $0
Q3 2022

Oct 07, 2022

SELL
$0.13 - $76.84 $3,205 - $1.89 Million
-24,656 Reduced 3.31%
720,133 $51.2 Million
Q2 2022

Jul 13, 2022

SELL
$72.62 - $79.98 $3.84 Million - $4.23 Million
-52,830 Reduced 6.62%
744,789 $57.3 Million
Q1 2022

Apr 14, 2022

BUY
$61.48 - $73.72 $10,205 - $12,237
166 Added 0.02%
797,619 $58.3 Million
Q4 2021

Jan 14, 2022

SELL
$53.63 - $62.52 $1.83 Million - $2.13 Million
-34,072 Reduced 4.1%
797,453 $49.7 Million
Q3 2021

Oct 22, 2021

BUY
$59.17 - $69.31 $49,998 - $58,566
845 Added 0.1%
831,525 $49.2 Million
Q2 2021

Jul 13, 2021

SELL
$61.91 - $67.42 $194,645 - $211,968
-3,144 Reduced 0.38%
830,680 $55.5 Million
Q1 2021

Apr 14, 2021

SELL
$59.34 - $66.74 $994,953 - $1.12 Million
-16,767 Reduced 1.97%
833,824 $52.6 Million
Q4 2020

Jan 14, 2021

SELL
$57.74 - $65.43 $105,895 - $119,998
-1,834 Reduced 0.22%
850,591 $52.8 Million
Q3 2020

Oct 19, 2020

SELL
$57.43 - $63.64 $131,399 - $145,608
-2,288 Reduced 0.27%
852,425 $51.4 Million
Q2 2020

Jul 15, 2020

SELL
$54.82 - $64.09 $10.5 Million - $12.3 Million
-191,366 Reduced 18.29%
854,713 $50.3 Million
Q1 2020

Apr 13, 2020

BUY
$46.4 - $67.43 $1.68 Million - $2.45 Million
36,283 Added 3.59%
1,046,079 $58.3 Million
Q4 2019

Jan 09, 2020

BUY
$49.21 - $64.19 $13.6 Million - $17.8 Million
277,193 Added 37.84%
1,009,796 $64.8 Million
Q3 2019

Oct 15, 2019

SELL
$42.77 - $50.71 $2 Million - $2.38 Million
-46,843 Reduced 6.01%
732,603 $37.2 Million
Q2 2019

Jul 17, 2019

SELL
$44.62 - $49.34 $2.77 Million - $3.06 Million
-62,014 Reduced 7.37%
779,446 $35.3 Million
Q1 2019

Apr 10, 2019

BUY
$45.12 - $53.8 $746,329 - $889,905
16,541 Added 2.01%
841,460 $40.1 Million
Q4 2018

Jan 14, 2019

BUY
$48.76 - $63.23 $2,779 - $3,604
57 Added 0.01%
824,919 $42.9 Million
Q3 2018

Oct 16, 2018

SELL
$55.19 - $62.25 $298,026 - $336,150
-5,400 Reduced 0.65%
824,862 $51.2 Million
Q2 2018

Jul 11, 2018

SELL
$50.53 - $62.98 $1.86 Million - $2.31 Million
-36,752 Reduced 4.24%
830,262 $45.9 Million
Q1 2018

Apr 12, 2018

SELL
$59.92 - $68.98 $2.23 Million - $2.56 Million
-37,159 Reduced 4.11%
867,014 $54.8 Million
Q4 2017

Jan 17, 2018

SELL
$59.94 - $65.35 $3.5 Million - $3.82 Million
-58,412 Reduced 6.07%
904,173 $55.4 Million
Q3 2017

Oct 16, 2017

BUY
$55.23 - $63.74 $53.2 Million - $61.4 Million
962,585
962,585 $61.4 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $126B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Gateway Investment Advisers LLC Portfolio

Follow Gateway Investment Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gateway Investment Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gateway Investment Advisers LLC with notifications on news.